

In the Claims

Claim 1 (Previously amended): A method for treating a sensory, motor and/or cognitive deficit wherein said method comprises the intracerebral administration of hematopoietic stem cells to a patient in need of such treatment.

Claim 2 (Previously amended): The method, according to claim 1, which comprises intracerebral transplantation of said hematopoietic stem cells into a damaged brain.

Claim 3 (Previously amended): The method, according to claim 1, wherein the treatment is for a condition selected from the group consisting of Alzheimer's disease, Parkinson's disease, Korsakoff's disease and Creuzfeld-Jacob disease.

Claim 4 (Previously amended): The method, according to claim 1, wherein said hematopoietic stem cells are conditionally immortal.

Claim 5 (Previously amended): The method, according to claim 4, wherein said hematopoietic stem cells comprise a temperature sensitive oncogene which is not expressed at a temperature above 35 °C.

Claim 6 (Currently amended): The method, according to claim 5, wherein said oncogene expresses the SV40 T- antigen.

Claims 7-9 (Cancelled)

Claim 10 (Previously amended): A pharmaceutical composition for treating a sensory, motor and/or cognitive deficit, wherein said composition comprises hematopoietic stem cells and a pharmaceutically acceptable carrier.

Claim 11 (Previously amended): The composition, according to claim 10, wherein said hematopoietic stem cells are conditionally immortal.

Claim 12 (Previously amended): The composition, according to claim 11, wherein the hematopoietic stem cells comprise a temperature sensitive oncogene which is not expressed at a temperature above 35°C.

Claim 13 (Previously added): The composition, according to claim 12, wherein the oncogene expresses SV40 T-antigen.

Claim 14 (Cancelled)

Claim 15 (New): The method, according to claim 1, wherein the patient is human.

Claim 16 (New): The method, according to claim 15, wherein the hematopoietic stem cells are human cells.

Claim 17 (New): The method, according to claim 1, wherein said intracerebral administration is carried out by microsyringe infusion.

Claim 18 (New): The method, according to claim 1, further comprising monitoring the patient using sensor, motor and/or cognitive tests after said intracerebral administration.

Claim 19 (New): The method, according to claim 1, wherein said intracerebral administration results in improved sensory, motor and/or cognitive function.

Claim 20 (New): The composition, according to claim 10, wherein said hematopoietic stem cells are human cells.